Clearside Releases Phase II RVO Results (OIS@AAO 2016) скачать в хорошем качестве

Clearside Releases Phase II RVO Results (OIS@AAO 2016)

"Posterior Segment Company Showcase: Clearside Biomedical" panel from Healthegy's OIS@AAO 2016: Presenter: Daniel White, President & CEO – Clearside Biomedical Dosing of the suprachoroidal space with Zuprata, Clearside Biomedical’s proprietary triamcinolone formulation, can provide high bioavailability of drug to the retina and choroid while avoiding the anterior segment and minimizing the potential for side effects associated with steroid treatments like elevated intraocular pressure (IOP) and cataracts, Clearside president and CEO Daniel White said during the Posterior Segment Company Showcase at OIS@AAO 2016. In the treatment of retinal vein occlusion, Zuprata improved vision at earlier time points and the improvements were maintained for at least three months, reducing the need for additional intravitreal injections of anti-VEGF, White said. As he explained, the suprachoroidal injection platform gives Clearside “exclusive and proprietary access via a microinjector to 17 cm2 of the human eye through the suprachoroidal space.” Read More on Clearside Biomedical Here: http://ois.net/clearside-releases-pha... For more on Ophthalmology Innovation News & Events visit: http://ois.net/